STEREOTAXIS INC (NYSEARCA:STXS) Stock Falls 9.5% After Q3 2025 Revenue Miss

Recent Performance

STEREOTAXIS INC (NYSEARCA:STXS) experienced a sharp decline in after-hours trading following the release of its third-quarter 2025 financial results. The stock fell approximately 9.5% as investors digested the earnings report, a significant reaction that overshadowed the stock's relatively flat performance over the past week and month. This immediate market response suggests a negative reception to the company's quarterly figures, particularly in the context of analyst expectations.

Q3 2025 Financial Results Versus Estimates

The company's financial performance for the quarter ended September 30, 2025, presented a mixed picture when measured against Wall Street forecasts. Stereotaxis reported revenue and earnings that diverged from analyst consensus estimates in distinct ways.

• Revenue: The company reported revenue of $7.46 million for the quarter. This figure fell short of the analyst estimate of $8.60 million, representing a revenue miss of approximately 13.3%.
• Earnings Per Share (EPS): Stereotaxis reported a non-GAAP loss per share of $0.03. While still a loss, this was a narrower deficit than the estimated loss of $0.0612 per share, meaning the company beat the earnings estimate by over 50%.

The market's negative reaction, despite the earnings beat, indicates that investors may be placing greater emphasis on the top-line revenue miss. In growth-oriented sectors like surgical robotics, revenue generation and sales growth are often viewed as critical indicators of market traction and future potential, which can outweigh a quarterly earnings beat, especially when the company remains unprofitable.

Press Release Summary and Future Outlook

The press release announced Stereotaxis's financial results for the third quarter of 2025, reinforcing its position as a pioneer in robotic surgical systems for endovascular intervention. The report detailed the company's key product offerings, including the Genesis RMN System and the Odyssey Solution, which are designed to enhance the treatment of arrhythmias and coronary disease through precise, robotic magnetic navigation.

The provided press release summary does not include a specific financial outlook or guidance from the company's management for the upcoming quarter or the full year. The absence of this forward-looking information is a neutral factor and does not, in itself, explain the negative market reaction. The sell-off appears to be a direct response to the reported revenue shortfall against expectations.

Analyst Estimates for Upcoming Periods

Looking ahead, analyst estimates provide a benchmark for Stereotaxis's future performance. For the fourth quarter of 2025, the consensus estimates are a revenue of approximately $10.06 million and a non-GAAP EPS loss of $0.051. For the full 2025 year, analysts are estimating sales of around $35.26 million. Investors will be watching closely to see if the company can return to meeting or exceeding these revenue projections in the next quarter.

For a detailed breakdown of historical earnings, future estimates, and analyst revisions, you can review the data here: STXS Earnings and Estimates.

---

Disclaimer: This article is for informational purposes only and is not intended as investment advice. The analysis is based on publicly available data and should not be construed as a recommendation to buy or sell any security. All investment decisions involve risk and should be made based on your own research and financial circumstances.